ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

brexpiprazole

Also written as “Brexpiprazole”, “OPC-34712” and “Brexpiprazole (OPC-34712)”.

Its studies are mostly in Schizophrenia · Depressive Disorder, Major · Stress Disorders, Post-Traumatic · Alzheimer Disease · Mania, led by 3 companies.

Drug pageBrexpiprazole: every studyAll 79 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 29, 202170 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsukaits history only600 open or runningphase 4since Mar 29, 2021Nov 24, 2008none ahead
H. Lundbeck90 open or runningphase 3since Mar 11, 2013Mar 11, 2013none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Dec 4, 2025Dec 4, 2025none ahead

Also a collaborator on its studies: Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of H. Lundbeck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2013First studies: 2 phase 3 studies in SchizophreniaFirst studyNCT01810380, NCT01810783
  2. Apr 4, 20132 phase 3 studies in Depressive Disorder, MajorNCT01837797, NCT01838681
  3. Sep 11, 20133 phase 3 studiesNCT01942785, NCT01942733, NCT01944969
  4. Nov 13, 2013Phase 3 study in Stress Disorders, Post-TraumaticNCT01987960 · 417 enrolled · United States, Estonia, Finland and more
  5. Apr 29, 2016Phase 3 study in SchizophreniaNCT02758067

TargetBeta

“Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131

Studies

All 9 H. Lundbeck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02758067Schizophrenia3WithdrawnJun 20160
NCT01987960Stress Disorders, Post-Traumatic · United States, Estonia, Finland and more3TerminatedOct 2015417
NCT01944969Depressive Disorder, Major · United States3TerminatedMay 201426
NCT01942785Depressive Disorder, Major · United States3CompletedJul 201455
NCT01942733Parasomnias3CompletedAug 201444
NCT01838681Depressive Disorder, Major · United States, Bulgaria, Canada and more3CompletedJun 20161,986
NCT01837797Depressive Disorder, Major · United States3TerminatedMay 2014129
NCT01810783Schizophrenia · United States, Estonia, Poland and more3CompletedDec 2015210
NCT01810380Schizophrenia · United States3CompletedDec 2014468

How it is read

Names in the registry

  • “Brexpiprazole”, 44 entries
  • “OPC-34712”, 17 entries
  • “Brexpiprazole (OPC-34712)”, 2 entries
  • “Brexpiprazole, OPC-34712”, 2 entries
  • “OPC-34712 + ADT”, 2 entries

Codes read as this program: OPDC34712.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.